9,193 results match your criteria nhl patients

Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1.

Adv Ther 2021 May 10. Epub 2021 May 10.

Celgene, a Bristol-Myers Squibb Company, Boudry, Switzerland.

Most patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have exhausted their treatment options and are deemed palliative. CD19-directed chimeric antigen receptor (CAR) T-cell therapy has recently been introduced as a new option for these patients. Lisocabtagene maraleucel (liso-cel) is an investigational CAR T-cell therapy that has shown promising activity in this setting. Read More

View Article and Full-Text PDF

High prevalence of plasma EBV DNA among the HIV positive individuals, with or without malignancies, attending the clinic at AIIMS, New Delhi.

Virusdisease 2021 Mar 19;32(1):137-139. Epub 2021 Mar 19.

Department of Internal Medicine, All India Institute of Medical Sciences, New Delhi, India.

Epstein-Barr Virus (EBV) is associated with the Hodgkin's and Non-Hodgkin's lymphoma (HL and NHL respectively). HIV is a risk factor for EBV infections and previously published data indicate that HIV infected individuals have higher chances of getting EBV infections compared to HIV uninfected individuals. Very limited information is available from India about the the prevalence of EBV in HIV positivity, with or without malignancy. Read More

View Article and Full-Text PDF

Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study.

Chin Med J (Engl) 2021 May 6. Epub 2021 May 6.

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 10021, China Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 20003, China Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China Department of Medical Oncology, 307 Hospital of Chinese People's Liberation Army, Beijing 100071, China Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer, Nanjing, Jiangsu 210009, China Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China Department of Hematology, The First Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, Zhejiang 310003, China Department of Hematology, Peking University Third Hospital, Beijing 100191, China Department of Oncology, Jilin University First Affiliated Hospital, Changchun, Jilin 130021, China Department of Hematology, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China Department of Hematology, Peking University Institute of Hematology, Peking University People's Hospital, Beijing 100044, China Department of Hematology, Guangdong General Hospital, Guangzhou, Guangdong 510062, China Department of Hematology and Research Laboratory of Hematology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150001, China Department of Hematology, Chinese PLA General Hospital, Beijing 100038, China Department of Hematology, Shanghai Ruijin Hospital, Shanghai 200020, China Department of Hematology, The Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, China Department of Drug Metabolism and Pharmacokinetics, Teva Branded Pharmaceutical Products R&D Inc., West Chester, PA 19380, USA.

Background: Bendamustine was approved in China on May 26th, 2019 by the National Medical Product Administration for the treatment of indolent B-cell non-Hodgkin lymphoma (NHL). The current study was the registration trial and the first reported evaluation of the efficacy, safety, and pharmacokinetics of bendamustine in Chinese adult patients with indolent B-cell NHL following relapse after chemotherapy and rituximab treatment.

Methods: This was a prospective, multicenter, open-label, single-arm, phase 3 study (NCT01596621; C18083/3076) with a 2-year follow-up period. Read More

View Article and Full-Text PDF

Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma - feasibility of MTX-based regimens in clinical routine.

Eur J Haematol 2021 May 7. Epub 2021 May 7.

Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine, University Hospital of Cologne, Cologne, Germany.

Background: Primary Central Nervous System Lymphoma (PCNSL) is a rare type of aggressive lymphoma of the central nervous system. Treatment strategies improved significantly over the past decades, differ regionally but mainly consist of rituximab and high-dosed methotrexate (MTX)-based therapies.

Methods: We assessed clinical outcomes of 100 patients with newly diagnosed PCNSL between 2010-2020 at the University Hospital of Cologne, Germany. Read More

View Article and Full-Text PDF

Patient, nurse, and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients.

Support Care Cancer 2021 May 6. Epub 2021 May 6.

iOMEDICO, Freiburg im Breisgau, Germany.

Purpose: The on-body injector (OBI) automatically delivers pegfilgrastim the day after chemotherapy (CTx), thus eliminating the need of return visits to the medical office for guideline-compliant pegfilgrastim administration. The CONVENIENCE study aimed to evaluate patient, nurse, and physician preferences as well as health economics for pegfilgrastim administration either with OBI or manually using a pre-filled syringe (PS).

Methods: Patients with early breast cancer, receiving two or three weekly anthracycline/cyclophosphamide or three weekly taxane-based CTx, and patients with Non-Hodgkin lymphoma (NHL) receiving first-line R-CHOP-14 or -21 were randomized 1:1 to receive both pegfilgrastim application forms for four consecutive CTx cycles in an alternating sequence starting either with OBI or PS. Read More

View Article and Full-Text PDF

Chemotherapy Treatments for Burkitt Lymphoma: Systematic Review of Interventional Studies.

Clin Lymphoma Myeloma Leuk 2021 Apr 3. Epub 2021 Apr 3.

Pharmaceutical Sciences Postgraduate Program, Federal University of Paraná, Curitiba, PR, Brazil; Department of Pharmacy, Federal University of Paraná, Curitiba, PR, Brazil. Electronic address:

Background: Burkitt lymphoma (BL) is an aggressive hematologic cancer. This study synthetized the evidence about the efficacy and safety of chemotherapy treatments used in patients with BL using the World Health Organization classification.

Materials And Methods: A systematic review of interventional studies was performed. Read More

View Article and Full-Text PDF

Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: a comprehensive review.

Cancer Sci 2021 May 3. Epub 2021 May 3.

Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.

Chemotherapy for non-Hodgkin lymphoma (NHL) in the hemodialysis (HD) patient is a challenging situation. Because many drugs are predominantly eliminated by the kidneys, chemotherapy in the HD patient requires special considerations concerning dose adjustments to avoid overdose and toxicities. Conversely, some drugs are removed by HD and may expose the patient to undertreatment, and therefore timing of drug administration in relation to HD sessions must be carefully planned. Read More

View Article and Full-Text PDF

Prevalence of chronic hepatitis B phases in Eritrean patients: a laboratory-based cross-sectional study.

BMC Gastroenterol 2021 May 1;21(1):198. Epub 2021 May 1.

Department of Immunoserology, National Health Laboratory (NHL), Asmara, Eritrea.

Background: Understanding the natural history of chronic hepatitis B (CHB) virus infection is important for determining optimal management and predicting prognosis in patients. The aim of this study was to determine the prevalence of different phases of CHB infection among Eritrean patients and to identify the proportion of patients who are eligible for treatment according to the latest American Association for the Study of Liver Diseases (AASLD) guidelines.

Methods: This cross-sectional study enrolled 293 CHB patients (213 males and 80 females) between Jan 2017 and Feb 2019. Read More

View Article and Full-Text PDF

Quality of life and fear of cancer recurrence in patients and survivors of non-Hodgkin lymphoma.

Psychol Health Med 2021 Apr 30:1-12. Epub 2021 Apr 30.

School of Psychology, University of New England, Armidale, Australia.

Non-Hodgkin lymphoma (NHL) is a common haematological cancer that is comprised of approximately 30 subtypes, of which Waldenström Macroglobulinemia (WM) is a rare incurable form. It is typically managed using a watch-and-wait strategy that can contribute to illness uncertainty which may result in fear of cancer recurrence (FCR) and poor health-related quality of life (QOL). However, few studies have examined the correlates of FCR and QOL in NHL patients, including WM patients. Read More

View Article and Full-Text PDF

The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy.

Br J Haematol 2021 Apr 29. Epub 2021 Apr 29.

EBMT ALWP Office Hôpital Saint-Antoine, Paris, France.

Chimaeric antigen receptor T-cell (CAR T) therapy has revolutionized the management of many haematological malignancies. It is associated with impressive disease responses in relapsed or refractory high-grade B-cell non-Hodgkin lymphoma (B-NHL) and acute lymphoblastic leukaemia (B-ALL) with durable remissions in a subset of patients. Historically, haematopoietic cell transplantation (HCT) has been the standard consolidation strategy for many of these patients who are now being treated with CAR T. Read More

View Article and Full-Text PDF

FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials.

Eur J Nucl Med Mol Imaging 2021 Apr 29. Epub 2021 Apr 29.

Department of Nuclear Medicine, University Hospital Regensburg, Regensburg, Germany.

Purpose: Fluorine-18 fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG PET/CT) is the standard for staging aggressive non-Hodgkin lymphoma (NHL). Limited data from prospective studies is available to determine whether initial staging by FDG PET/CT provides treatment-relevant information of bone marrow (BM) involvement (BMI) and thus could spare BM biopsy (BMB).

Methods: Patients from PETAL (NCT00554164) and OPTIMAL>60 (NCT01478542) with aggressive B-cell NHL initially staged by FDG PET/CT and BMB were included in this pooled analysis. Read More

View Article and Full-Text PDF

Effects of External Auditory Meatus Occlusion on Ocular Vestibular Evoked Myogenic Potentials Induced by Bone Conducted Sound.

Front Neurol 2021 13;12:659820. Epub 2021 Apr 13.

Department of Otolaryngology, Teikyo University School of Medicine Mizonokuchi Hospital, Kawasaki, Japan.

To facilitate more reliable recordings of the ocular vestibular evoked myogenic potentials (oVEMP) induced by bone-conducted sound using the B81 bone conduction transducer, we preliminarily studied the effects of external auditory meatus occlusion using an earplug on such oVEMP. Eight healthy volunteers (four males and four females, 26-48 years of age, mean age: 34. 5 years) and 14 patients with vestibular disease (2 males and 12 females, 18-59 years of age, mean age: 41. Read More

View Article and Full-Text PDF

Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations.

Cancers (Basel) 2021 Apr 25;13(9). Epub 2021 Apr 25.

Department of Pediatric Hematology, Oncology and BMT, University Hospital Muenster, 48149 Münster, Germany.

Despite poor survival, controversies remain in the treatment for refractory or relapsed pediatric non-Hodgkin lymphoma (r/r NHL). The current project aimed to collect international experience on the re-induction treatment of r/r NHL, hematopoietic stem cell transplantation (HSCT), risk factors associated with outcome, and to suggest treatment recommendations. Inclusion criteria were (i) refractory disease, disease progression or relapse of any NHL subtype except anaplastic large cell lymphoma, (ii) age < 18 years at initial diagnosis, (iii) diagnosis in/after January 2000. Read More

View Article and Full-Text PDF

Development of a Questionnaire for the Search for Occupational Causes in Patients with Non-Hodgkin Lymphoma: The RHELYPRO Study.

Int J Environ Res Public Health 2021 Apr 11;18(8). Epub 2021 Apr 11.

Service des Pathologies Professionnelles et de l'Environnement, CHI Créteil, F-94010 Créteil, France.

Non-Hodgkin lymphoma (NHL), multiple myeloma and chronic lymphocytic leukemia are possibly related to environmental and/or occupational exposure. The primary objective of this study was to develop a questionnaire for screening patients with these blood disorders who might benefit from a specialized consultation for possible recognition of the disease as an occupational disease. The study included 205 subjects (male gender, 67. Read More

View Article and Full-Text PDF

Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma.

Cancers (Basel) 2021 Apr 2;13(7). Epub 2021 Apr 2.

Department of Internal Medicine V-Hematology, Oncology & Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.

Chimeric antigen receptor T (CAR-T) cell therapy has proven to be very effective in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). However, infections-related either due to lymphodepletion or the CAR-T cell therapy itself-can result in severe and potentially life-threatening complications, while side effects such as cytokine release syndrome (CRS) might complicate differential diagnosis. Sixty-seven dosings of CAR-T cells in sixty adult patients with NHL (85%) and ALL (15%) receiving CAR-T cell therapy were assessed for infectious complications. Read More

View Article and Full-Text PDF

CRISPR-edited CART with GM-CSF knockout and auto secretion of IL6 and IL1 blockers in patients with hematologic malignancy.

Cell Discov 2021 Apr 27;7(1):27. Epub 2021 Apr 27.

The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.

Revolutionary CART therapy still faces the challenge of severe cytokine release syndrome (CRS). While IL6 and IL1 have been demonstrated as essential contributors, GM-CSF is one of the most abundant inflammatory cytokines secreted by CART and has also been suggested in contributing to CRS. To minimize GM-CSF production from CART to reduce its associated toxicity, we conducted a pilot study (ChiCTR2000032124) of CRISPR-edited GM-CSF knockout (KO) in CART secreting anti-IL6 scFv and IL1RA, with additional TCR KO for tracing edited CART. Read More

View Article and Full-Text PDF

Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma.

Blood Adv 2021 Apr;5(8):2245-2255

Fred Hutchinson Cancer Research Center, Seattle, WA.

CD19-directed chimeric antigen receptor (CAR) T-cell therapy has shown efficacy as a third-line or later treatment in patients with relapsed/refractory large B-cell lymphoma (LBCL). Using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire, we evaluated the impact of CAR T-cell treatment with lisocabtagene maraleucel (liso-cel) on health-related quality of life (HRQoL) and symptoms in patients with relapsed/refractory LBCL in the ongoing, open-label, nonrandomized TRANSCEND NHL 001 trial. Clinically meaningful improvement was observed in EORTC QLQ-C30 scores for global health status/QoL, based on a minimally important difference of 10 points at 2 to 18 months after liso-cel infusion. Read More

View Article and Full-Text PDF

Validation of an electronic algorithm for Hodgkin and non-Hodgkin lymphoma in ICD-10-CM.

Pharmacoepidemiol Drug Saf 2021 Apr 26. Epub 2021 Apr 26.

Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School, Boston, Massachusetts, USA.

Purpose: Lymphoma is a health outcome of interest for drug safety studies. Studies using administrative claims data require the accurate identification of lymphoma cases. We developed and validated an International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM)-based algorithm to identify lymphoma in healthcare claims data. Read More

View Article and Full-Text PDF

Thorium-227-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study.

Cancer Biother Radiopharm 2021 Apr 21. Epub 2021 Apr 21.

Department of Haematology, University College London Hospital, London, United Kingdom.

BAY 1862864 is an α-particle emitting thorium-227-labeled CD22-targeting antibody. This first-in-human dose-escalation phase I study evaluated BAY 1862864 in patients with CD22-positive relapsed/refractory B cell non-Hodgkin lymphoma (R/R-NHL). BAY 1862864 intravenous injections were administered at the starting thorium-227 radioactivity dose of 1. Read More

View Article and Full-Text PDF


Afr J Infect Dis 2020 31;14(2):42-47. Epub 2020 Jul 31.

Hematology Department, Koç University Medical School, Istanbul, Turkey.

Background: Human immunodeficiency virus (HIV) is a global health concern with major risks for opportunistic infections and predisposition to malignancies including Kaposi sarcoma associated with Human Herpes Virus-8 (HHV-8) and non-Hodgkin lymphoma (NHL) commonly associated with Epstein Barr Virus (EBV). Although the exact mechanisms of predisposition to certain malignancies are unclear, HIV (+) cancer patients typically have poorer prognosis.

Materials And Methods: We included all five HIV positive NHL patients receiving antiretroviral therapy (ART) and chemotherapy in our clinic and aim to determine their follow-up outcomes associated with ART. Read More

View Article and Full-Text PDF

Primary esophageal non-Hodgkin's lymphoma: demographics, clinical characteristics, histopathologic types, and survival in 179 patients from the SEER program and systematic review of the literature.

Esophagus 2021 Apr 20. Epub 2021 Apr 20.

Public Health and Epidemiological Studies Group, Cardiovascular Foundation of Colombia, Floridablanca, Colombia.

Background: The most frequent site for the extranodal appearance of primary non-Hodgkin's lymphomas (NHL) is the gastrointestinal (G.I.) tract. Read More

View Article and Full-Text PDF

Performance After Concussion in National Hockey League Players.

J Athl Train 2021 Apr;56(4):404-407

School of Medicine, University of Maryland, Baltimore.

Context: Concussions in ice hockey players are an interesting area of study due to the fast-paced and high-impact nature of the sport. Recently, researchers have focused on player performance after return from concussion to evaluate subclinical deficits that were previously missed.

Objective: To examine National Hockey League (NHL) player performance from 2013 to 2019 and compare performance before a concussion with performance immediately after recovering to assess the current NHL return-to-play protocol. Read More

View Article and Full-Text PDF

Case Report: Clinical Responses to Tislelizumab as a First-Line Therapy for Primary Hepatocellular Carcinoma With B-Cell Indolent Lymphoma.

Front Immunol 2021 31;12:634559. Epub 2021 Mar 31.

Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Background: As an emerging therapy with a promising efficacy, immunotherapy has been widely used in the treatment of solid tumors and hematologic malignancies. This clinical study compares the efficacy of tislelizumab, a domestic immune checkpoint inhibitor (ICI), to that of sorafenib when used as a first-line therapeutic option in hepatocellular carcinoma (HCC), and the concurrence of HCC and non-Hodgkin's lymphoma (NHL) is rare, especially in the treatment of ICIs.

Case Presentation: A 61-year-old patient presenting with primary HCC and indolent B-cell lymphoma had a partial clinical response to tislelizumab for his primary HCC. Read More

View Article and Full-Text PDF

Analysis of the Expression of the TRBC1 in T lymphocyte tumors.

Indian J Hematol Blood Transfus 2021 Apr 24;37(2):271-279. Epub 2020 Sep 24.

Department of Pathology and Laboratory Medicine, Hebei Yanda Lu Daopei Hospital, No.2 Siplan Road, Yanjiao Development Zone, Langfang, 065201 Hebei China.

T cell therapy represents a new class of immunotherapies garnering considerable attention. T cell receptor beta chain constant region 1 (TRBC1) is partially expressed in subsets of normal T cells. However, the immunotherapy of T lymphocyte tumors is rarely validated in clinical trials. Read More

View Article and Full-Text PDF

A Phase II Trial of Melphalan Based Reduced-Intensity Conditioning for Transplantation of T-Replete HLA-Haploidentical Peripheral Blood Stem Cells with Posttransplant Cyclophosphamide in Patients with Hematologic Malignancies.

Adv Hematol 2021 23;2021:8868142. Epub 2021 Mar 23.

Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA.

T-replete haploidentical donor transplants using posttransplant cyclophosphamide (haplo) have greatly expanded donor availability and are increasingly utilized. Haplo were originally performed using truly nonmyeloablative conditioning and a bone marrow graft. We have also developed myeloablative conditioning and peripheral blood stem cell (PBSC) grafts for use with haplo. Read More

View Article and Full-Text PDF

CAR T cells Targeting Human Immunoglobulin Light Chains Eradicate Mature B Cell Malignancies While Sparing a Subset of Normal B Cells.

Clin Cancer Res 2021 Apr 15. Epub 2021 Apr 15.

Lineberger Comprehensive Cancer Center, University of North Carolina.

Purpose: CD19-redirected chimeric antigen receptor (CAR.CD19) T cells promote clinical responses in patients with relapsed/refractory B cell non-Hodgkin lymphomas (NHL) and chronic lymphocytic leukemia (CLL). However, patients showing sustained clinical responses after CAR. Read More

View Article and Full-Text PDF

Hematopoietic Stem Cell Transplantation in T-cell and NK-cell lymphomas-Update on Recent Advances.

Transplant Cell Ther 2021 Apr 12. Epub 2021 Apr 12.

Department of Hematology-Oncology, National University Cancer Institute, Singapore; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address:

Mature T- and natural killer (NK)-cell non-Hodgkin lymphoma (T-cell NHL) have a poor prognosis. Data from existing retrospective and prospective studies has suggested that high-dose chemotherapy (HDT) followed by autologous hematopoietic cell transplantation (auto-HCT) may improve the survival in patients with chemosensitive disease, either in the upfront or salvage setting. Auto-HCT is currently recommended to be used as frontline consolidation in peripheral T-cell lymphoma not otherwise specified (PTCL-nos), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma-anaplastic lymphoma kinase (ALCL-ALK) negative, NK/T-cell (disseminated), and enteropathy-associated T-cell lymphoma (EATL). Read More

View Article and Full-Text PDF

Total body irradiation of bone marrow transplant using helical TomoTherapy with a focus on the quality of dose contribution at junction target volumes.

Strahlenther Onkol 2021 Apr 14. Epub 2021 Apr 14.

Department of Radiotherapy, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad, India.

Purpose: Total body irradiation (TBI) can be safely delivered on TomoTherapy (Accuray, Sunnyvale, CA, USA) in both pediatric and adult patients with proper imaging and planning despite the length constraint of 135 cm. To overcome this limitation, two CT (Computed Tomography) scans (CT1& CT2) are taken in patients above 135 cm in height. Adequate junction dose coverage is important in TBI. Read More

View Article and Full-Text PDF

Angiogenesis imaging study using interim [F] RGD-K5 PET/CT in patients with lymphoma undergoing chemotherapy: preliminary evidence.

EJNMMI Res 2021 Apr 12;11(1):37. Epub 2021 Apr 12.

Department of Nuclear Medicine, Henri Becquerel Cancer Center, Rouen University Hospital & QuantIF-LITIS, University of Rouen, 1 rue d'amiens, 76000, Rouen, France.

Background: Our aim was to measure the impact of two cycles of standard chemotherapy on tumoural neoangiogenesis by [F] fluorine arginine-glycine-aspartic (RGD-K5) positron emission tomography-computed tomography (PET) on patients presenting with lymphoma. Nineteen patients at Rouen's Henri Becquerel Cancer Centre were prospectively included. Fluorodeoxyglucose (FDG) and RGD-K5 PET were performed before (C0) and after (C2) two cycles of chemotherapy. Read More

View Article and Full-Text PDF

Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines.

BMC Cardiovasc Disord 2021 Apr 12;21(1):170. Epub 2021 Apr 12.

Department of Diagnostic Imaging, Universidade Federal de São Paulo (UNIFESP), Rua Napoleão de Barros 800, Vila Clementino, São Paulo, 04024-002, Brazil.

Background: The use of anthracycline-based chemotherapy is associated with the development of heart failure, even years after the end of treatment. Early detection of cardiac dysfunction could identify a high-risk subset of survivors who would eventually benefit from early intervention. Cardiac magnetic resonance feature-tracking (CMR-FT) analysis offers a practical and rapid method to calculate systolic and diastolic strains from routinely acquired cine images. Read More

View Article and Full-Text PDF